Clinical Study ProgressProMIS announced that it received approval from the independent Data and Safety Monitoring Board (DSMB) to advance to the final dose escalation cohort in its ongoing P1b study of PMN310 for Alzheimer's disease.
Financial StabilityProMIS further strengthened its balance sheet by raising $21.6M in gross proceeds through July 2025 financing activities and launching an ~$18M ATM offering, which combined should provide funding into 2026.
Safety And EfficacyThe recommendation followed the review of fully enrolled cohort 2, which demonstrated no cases of amyloid-related imaging abnormalities, a significant safety risk in existing amyloid treatments.